LumiraDx high sensitivity point of care Platform
The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays, in a portable, easy to use point of care solution.
LumiraDx SARS-CoV-2 Antigen Test
The LumiraDx SARS-CoV-2 Ag Test is a microfluidic immunofluorescence assay for direct and qualitative detection of nucleocapsid proteins in nasal swab specimens from patients suspected of COVID-19.
The Test, which has received Emergency Use Authorization from the FDA will help meet the global challenge of delivering fast and cost-efficient COVID-19 tests in community care settings.
For integrated connectivity, LumiraDx Connect ensures the easy, secure transfer of results from the LumiraDx Instrument to Connect Manager or to a patient’s electronic health record.